A regulatory requirement non-interventional study to monitor the safety and effectiveness of Ofev (Nintedanib, 150mg/100mg, BID) in Korean patients First published 07/07/2021 Last updated 10/12/2024 EU PAS number:EUPAS41912 Study Finalised